Bullish Gator

Illumina, Inc. (ILMN)

Technical, fundamental, and sentiment analysis with recent related videos.

Stock Hub•Last Updated: 2026-11-21

Bullish Gator Rating
Neutral

ILMN rates Neutral overall. The fundamental read is bullish: the company passes 8 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 5.74); revenue fell an average of 1.8% a year over the last three fiscal years. The technical picture is bearish: price is 6.5% above the 200-day moving average; 22.3% below the 50-day; the 50-day moving average sits above the 200-day (Golden cross state). Sentiment is bearish (composite 44/100), based on 3 news articles from recent coverage.

Fundamental Rating
Bullish

Revenue 3-year avg -1.8%. Net income 3-year avg N/A.

Technical Rating
Bearish

Price vs 20DMA -15.2%. RSI 33.59. Bollinger state: Inside Bands.

Sentiment Rating
Bearish

Composite score 44/100 from the AI judge, based on 3 news items, 0 television segments, and 0 videos.

Latest Market Read

Illumina’s three badges disagree, so the overall rating sits at Neutral. The Fundamental badge is Bullish, driven by a blend of revenue and net-income trends plus strength on the Piotroski F-Score and Altman Z-Score, even though revenue averaged -1.8 percent per year over three years. The Technical badge is Bearish: price sits 15.2 percent below the 20-day moving average (20DMA), the Relative Strength Index (RSI), a momentum reading, is 33.6, and price is inside the Bollinger Bands. Sentiment is Bearish at 44/100, and that negative tone plus weak momentum offset the fundamental positives.

Recent news: Coverage is mixed but leans negative: Illumina disclosed voluntary Class II recalls for several diagnostic sequencing instruments over cybersecurity vulnerabilities, a story that coincided with a 1-day 4.45% drop, a 30-day 25.11% decline and a GDELT tone of 38/100. A bullish counterpoint highlights a 111.2% three-year share gain and Illumina's role in Singapore's SG-INSIGHT precision medicine effort that could support long-term revenue, but the recalls and weak recent price action dominate the near-term outlook.

Latest Videos

  • No qualified videos yet.